ImmunityBio's 700% Revenue Surge Spurs Hedge Fund Bets on Anktiva
TL;DR
ImmunityBio reported 2025 revenue of about $113 million, a 700% year-over-year increase, with Q4 revenue of $38.3 million up 431% driven by rapid scaling of lead oncology therapy Anktiva; major funds such as Citadel and Renaissance increased their holdings, signaling investors are betting on faster commercialization rather than trial risk as the stock climbs year-to-date.
- ImmunityBio's 700% Revenue Boom Becomes Citadel's Latest I‑Told‑You‑So Benzinga
- ImmunityBio (IBRX) Extends Gains to 10th Day on 700% Anktiva Sales Jump; Time to Book Profits? Yahoo Finance
- This Biotech Stock Is Up More Than 100% This Year. Why It’s Soaring Again Today. Barron's
- ImmunityBio: Why I Am Upgrading To A Buy For 2026 (NASDAQ:IBRX) Seeking Alpha
- Patrick Soon-Shiong’s cancer drug approved by Saudi FDA NewsNation
Want the full story? Read the original reporting
Read on Benzinga